Lymphoseek

ApprovedSmall molecule

NNavidea Biopharmaceuticals

Lymphoseek is one of 145 small molecule programs targeting Breast Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

144

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Endometrial CancerActive, not recruiting

Breast CancerApproved

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Active, not recruiting

Endometrial CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lymphoseek

NNavidea Biopharmaceuticals

Approved

3 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Avastin

Prolia

14 5

DATROWAY

Daiichi Sankyo

Preclinical

4 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Voltaren

Novartis

Preclinical

1 8

Zinecard

CChildren's Oncology Group

Preclinical

2 9

Chirocaine

PPurdue Pharma LP

Preclinical

1 10

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer3 trials

Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer

Unknown status·AAnna Cruceta·Phase 4·NCT04261179·30 enrolled

Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer

Completed·KKettering Health Network·Phase 4·NCT02287675·40 enrolled

Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma

Completed·NNavidea Biopharmaceuticals·Phase 3·NCT00671918·186 enrolled

Metastatic1 trial

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Completed·EEben Rosenthal·Phase 2·NCT03405142·3 enrolled

Melanoma1 trial

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

Completed·NNavidea Biopharmaceuticals·Phase 3·NCT01106040·163 enrolled

Endometrial Cancer1 trial

Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer

Terminated·SStanford University·Phase 2·NCT04511026·6 enrolled

Prospective1 trial

A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus

Withdrawn·CCardinal Health 414, LLC·Phase 2·NCT02857608

1 more indication

Head and Neck Squamous Cell Carcinoma1 trial

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Terminated·NNavidea Biopharmaceuticals·Phase 3·NCT00911326·101 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Lymphoseek. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lymphoseek compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lymphoseek. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Navidea Biopharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNavidea Biopharmaceuticals

Lymphoseek

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer3 trials

Metastatic1 trial

Melanoma1 trial

Endometrial Cancer1 trial

Prospective1 trial

Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News